Why Aurora Cannabis’ (TSX:ACB) “Different” Strategy Has Me Licking My Chops

Hedge fund manager Nelson Peltz is licking his chops with Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) and its unique strategy. Here’s why you should be too!

| More on:
Portrait of woman having fun in the street.

Image source: Getty Images

Many investors have scooped up Aurora Cannabis (TSX:ACB)(NYSE:ACB) in hopes that a big-league investor (perhaps a pharmaceutical giant) will jump in with a big, fat investment and send shares of Aurora skyrocketing into the stratosphere.

Aurora is one of the big cannabis players that still lacks a dance partner. With cannabis peers like Canopy Growth (TSX:WEED)(NYSE:CGC) and Cronos Group now ripping up the dance floor with a deep-pocketed partner, the thesis at this juncture appears to be that Aurora is the marijuana player with the largest number of catalysts and the most room to run.

Given the industry trends, it seems like it’ll just be a matter of time before Aurora lands initial investment from a well-established firm, so it’s not a mystery as to why many millennials prefer Aurora over current top dog Canopy Growth.

In a prior piece, I highlighted the advantages that Canopy gained by having Constellation Brands standing in its corner. The cannabis industry is ridiculously volatile, and Constellation’s vote of confidence served as a support level. Given that Canopy’s pockets are now that much deeper, Canopy CEO Bruce Linton and company now have more financial flexibility to take advantage of opportunities as they arise.

There are significant pros to already having a behemoth of an investor (such as more downside protection), but there are also major cons that I believe investors may be overlooking. Having a major investor could seriously limit long-term upside, and for pot investors, that’s simply unacceptable.

So, where’s that big-league investor, Aurora?

In a recent interview conducted by MarketWatch, Aurora CEO Cam Battley shed light on why his firm hadn’t signed on a major deal with a behemoth as Canopy while other peers have.

Battley stated that Aurora is “taking a different approach” on the advice of hedge fund manager Nelson Peltz, who was strongly against “selling [Aurora] shareholders short” as the value of the company was still rising rapidly.

While selling a massive chunk of shares to a big-league investor is an easy out, Battley has made it clear to investors that his firm in it for the long haul, and as industry consolidation continues at a rapid rate, we’ll likely see Aurora as a consolidator and not as a takeover target as many investors have speculated.

Peltz and Battley both have a good point.

If the cannabis industry continues growing at this triple-digit rate, it’d prove to be an unwise move to take the first big offer that comes rolling in. Instead of buttering up for an acquisition, Battley and company are focused on growth and innovation.

In a decade or so down the road, we’ll likely see the pool of cannabis players decrease substantially. My bet is that Aurora will still trade on the TSX, but at a much heftier multiple. And as Constellation Brands gradually gobbles up what remains of Canopy’s shares, from a longer-term perspective, it’s looking as though there’s way more upside to be had with Aurora stock.

Even though the lack of a major dance partner puts Aurora stock at a greater risk of downside alongside broader industry-wide moves, I think pot investors should still lean toward Aurora with their pot portfolios.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »